One year's experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis

Offner, G.; Hoyer, Peter F.; Latta, Kay; Winkler, L; Brodehl, J.; Scigalla, P.

doi:10.1007/bf00869830

Cited by 36 publications

(20 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Good results have also been obtained with the intravenous treatment of children undergoing CAPD or continuous cycling peritoneal dialysis [1,18]; this mode of therapy, however, is not practical. Subcutaneous administration of erythropoietin has been advocated since good therapeutic results have been obtained in several groups of patients with anaemia due to renal disease [1,5,14,20,23].…”

Section: Discussionmentioning

confidence: 93%

Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis

1992

View full text Add to dashboard Cite

In 16 children treated by continuous ambulatory peritoneal dialysis (CAPD) recombinant human erythropoietin was administered intraperitoneally for the treatment of renal anaemia. The mean treatment period was 8.3 months. Mean haemoglobin values increased from 4.9 mmol/l at start of therapy to 6.2 after 6 months. While 11 out of 16 children needed a total of 22 transfusions during the 6 months prior to therapy, no transfusions were needed after initiation of therapy. Patients started with a dose of 300 units/kg per week. After 6 months of therapy, the mean dose was 370 and after 12 months 279 units/kg per week. No major side-effects were observed. The incidence of peritonitis was not increased. We conclude that intraperitoneal administration of erythropoietin is effective in the treatment of renal anaemia in children treated by CAPD.

show abstract

Section: Discussionmentioning

confidence: 93%

Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis

1992

View full text Add to dashboard Cite

show abstract

“…It is also possible that due to direct action of erythropoietin on voltage-independent Ca 2+ channels in the VMSCs, the sensitivity of the latter to the vasodilatory action of NO may be diminished [60] . Erythropoietin has been reported to exacerbate HTN in both non-dialyzing and dialyzing CKD children [61,62] . This complication can be ameliorated by reducing the dose of erythropoietin.…”

Section: Volume Overload Due To Chronic Anaemiamentioning

confidence: 99%

Pre-treatment considerations in childhood hypertension due to chronic kidney disease

Olowu

2015

WJN

View full text Add to dashboard Cite

Hypertension (HTN) develops very early in childhood chronic kidney disease (CKD). It is linked with rapid progression of kidney disease, increased morbidity and mortality hence the imperative to start antihypertensive medication when blood pressure (BP) is persistently > 90 th percentile for age, gender, and height in non-dialyzing hypertensive children with CKD. HTN pathomechanism in CKD is multifactorial and complexly interwoven. The patient with CKD-associated HTN needs to be carefully evaluated for co-morbidities that frequently alter the course of the disease as successful treatment of HTN in CKD goes beyond life style modification and anti-hypertensive therapy alone. Chronic anaemia, volume overload, endothelial dysfunction, arterial media calcification, and metabolic derangements like secondary hyperparathyroidism, hyperphosphataemia, and calcitriol deficiency are a few co-morbidities that may cause or worsen HTN in CKD. It is important to know if the HTN is caused or made worse by the toxic effects of medications like erythropoietin, cyclosporine, tacrolimus, corticosteroids and non-steroidal anti-inflammatory drugs. Poor treatment response may be due to any of these co-morbidities and medications. A satisfactory hypertensive CKD outcome, therefore, depends very much on identifying and managing these co-morbid conditions and HTN promoting medications promptly and appropriately. This review attempts to point attention to factors that may affect successful treatment of the hypertensive CKD child and how to attain the desired therapeutic BP target.

show abstract

“…We, as well as others [ 1,[6][7][8][9], have shown that low-dose subcutaneously administered rhEPO is ef fective in treating the anemia of ESRD. Intraperitoneal administration, though effective, is costly, requiring doses 5 to 10 times that used subcutaneously [10][11][12], In addi tion, an increased frequency of peritonitis has been ob served with intraperitoneal administration [13,14].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Once- versus Thrice-Weekly Subcutaneous Recombinant Human Erythropoietin in Children Receiving Continuous Cycling Peritoneal Dialysis

Ongkingco

Ruley²,

Turner³

et al. 1994

Am J Nephrol

View full text Add to dashboard Cite

The subcutaneous administration of recombinant human erythropoietin is effective in the treatment of anemia of end-stage renal disease. Single-dose pharmacokinetic studies suggest the possibility of less frequent dosing via the subcutaneous route. In this study, dosing once-weekly was as effective as thrice-weekly subcutaneous dosing in maintaining the corrected hematocrit in a group of children receiving continuous cycling peritoneal dialysis. This regimen was preferred by and benificial to both patients and their parents.

show abstract

One year's experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis

Cited by 36 publications

References 10 publications

Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis

Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis

Pre-treatment considerations in childhood hypertension due to chronic kidney disease

Efficacy of Once- versus Thrice-Weekly Subcutaneous Recombinant Human Erythropoietin in Children Receiving Continuous Cycling Peritoneal Dialysis

Contact Info

Product

Resources

About